Besides the acute phase gastrointestinal effects which may lead to up to 10% of people discontinuing the drugs, there are other potential GI side effects of obstruction, excessive loss of muscle mass, and potentially association with some eye disease adverse events
Pantalone, DO, ECNU Incretin-based drug therapies such as glucagon-like peptide-1 (GLP-1) receptor agonists and dual glucose-dependent insulinotropic peptide and GLP-1 receptor agonists are rapidly becoming first-line options for treating type 2 diabetes
On the other hand, whole foods aid digestion and balance your gut bacteria, supporting GLP-1 release
Lower maintenance doses (8mg instead of 12mg) still provide excellent results while reducing side effects
They all have to have some bona fide reason
In the main 80-week trial, the highest dose produced an average weight loss of 28.3% among people who stayed on treatment, and 25.0% when everyone who started is counted